| Title: |
Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK/06/016) |
| Authors: |
Staffurth, John N.; Haviland, Joanne S.; Wilkins, Anna; Syndikus, Isabel; Khoo, Vincent; Bloomfield, David; Parker, Chris; Logue, John; Scrase, Christopher; Birtle, Alison; Malik, Zafar; Panades, Miguel; Eswar, Chinnamani; Graham, John; Russell, Martin; Ferguson, Catherine; O?Sullivan, Joe M.; Cruickshank, Clare A.; Dearnaley, David; Hall, Emma |
| Publisher Information: |
Elsevier |
| Publication Year: |
2021 |
| Collection: |
Cardiff University: ORCA (Online Research @ Cardiff) |
| Description: |
Background Moderate hypofractionation is the recommended standard of care for localised prostate cancer following the results of trials including Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer (CHHiP). Evaluation of long-term patient-reported outcomes (PROs) is important to confirm safety and enhance patient information. Objective To determine whether 5-yr PROs from the CHHiP quality of life (QoL) substudy confirm 2-yr findings and assess patterns over follow-up. Design, setting, and participants A phase III randomised controlled trial recruited from 2002 to 2011. The QoL substudy completed accrual in 2009; participants were followed up to 5 yr after radiotherapy. Analyses used data snapshot taken on August 26, 2016. A total of 71 radiotherapy centres were included in the study (UK, Republic of Ireland, Switzerland, and New Zealand); all 57 UK centres participated in the QoL substudy. CHHiP recruited 3216 men with localised prostate cancer (cT1b-T3aN0M0). Intervention Conventional (74 Gy/37 fractions/7.4 wk) or hypofractionated radiotherapy (60 Gy/20 fractions/4 wk or 57 Gy/19 fractions/3.8 wk) was delivered with intensity-modulated techniques. Outcome measurements and statistical analysis University of California Los Angeles Prostate Cancer Index, Short Form 36 and Functional Assessment of Cancer Therapy—Prostate, or Expanded Prostate Cancer Index Composite and Short Form 12 questionnaires were administered at baseline, before radiotherapy, at 10 wk, and at 6, 12, 18, 24, 36, 48, and 60 mo after radiotherapy. The QoL primary endpoint was overall bowel bother. Results and limitations The QoL substudy recruited 2100 patients; 1141 5-yr forms were available from 1957 patients still alive (58%). There were no statistically significant differences in 5-yr prevalence of overall “moderate or big” bowel bother: 19/349 (5.4%), 29/381 (7.6%), and 21/393 (5.3%) for 74, 60, and 57 Gy, respectively; overall urinary or sexual bother at 5 yr was similar between schedules. Bowel ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://orca.cardiff.ac.uk/id/eprint/157785/1/STAFFURTH,%20JOHN%20-%20CHHiP%205yr%20QoL%20EurUrol%20paper.pdf; Staffurth, John N. https://orca.cardiff.ac.uk/view/cardiffauthors/A0702394.html orcid:0000-0002-7834-3172 orcid:0000-0002-7834-3172, Haviland, Joanne S., Wilkins, Anna, Syndikus, Isabel, Khoo, Vincent, Bloomfield, David, Parker, Chris, Logue, John, Scrase, Christopher, Birtle, Alison, Malik, Zafar, Panades, Miguel, Eswar, Chinnamani, Graham, John, Russell, Martin, Ferguson, Catherine, O?Sullivan, Joe M., Cruickshank, Clare A., Dearnaley, David and Hall, Emma 2021. Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK/06/016). European Urology Oncology 4 (6) , pp. 980-992. 10.1016/j.euo.2021.07.005 https://doi.org/10.1016/j.euo.2021.07.005 file https://orca.cardiff.ac.uk/id/eprint/157785/1/STAFFURTH,%20JOHN%20-%20CHHiP%205yr%20QoL%20EurUrol%20paper.pdf |
| DOI: |
10.1016/j.euo.2021.07.005 |
| Availability: |
https://orca.cardiff.ac.uk/id/eprint/157785/; https://doi.org/10.1016/j.euo.2021.07.005 |
| Rights: |
cc_by_4_0 |
| Accession Number: |
edsbas.5CA711E1 |
| Database: |
BASE |